Although rare, pulmonary arterial hypertension (PAH) is associated with substantial morbidity and a median survival of approximately 7 years, even with treatment. Current medical therapies have a primarily vasodilatory effect and do not modify...

Balloon pulmonary angioplasty (BPA) has been proven effective for addressing technically inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, the effectiveness of BPA in technically operable CTEPH patients who...

'Fungi' is part of the Inflammation and Infection Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD. 

In this Community Call, we discussed:

• Altered Smooth Muscle Cell Histone Acetylome by the SPHK2/S1P Axis Promotes Pulmonary Hypertension
• Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
• Impact on Pulmonary Hypertension Hemodynamic Classification Based on the Methodology Used to Measure Pulmonary Artery Wedge Pressure and Cardiac Output

In this Community Call, we discussed: 

• Targeting Wnt-ß-Catenin-FOSL Signaling Ameliorates Right Ventricular Remodeling
• Win Statistics in PAH Clinical Trials
• Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol

'Viruses' is part of the Inflammation and Infection Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD. 

In this Community Call, we discussed: 

• Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension
• Elastin stabilization prevents impaired biomechanics in human pulmonary arteries and pulmonary hypertension in rats with left heart disease

In this Community Call, we discussed:

• Wnt7a deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension
• Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials